Hexima Limited (HXL.AX)
AUD 0.01
(0.0%)
AUD 0.01
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | - AUD | -100.0% |
| 2023 | 1.48 Million AUD | -74.45% |
| 2022 | 5.81 Million AUD | 42.35% |
| 2021 | 4.08 Million AUD | 4528.99% |
| 2020 | 88.18 Thousand AUD | -88.94% |
| 2019 | 797.67 Thousand AUD | -54.08% |
| 2018 | 1.73 Million AUD | -3.84% |
| 2017 | 1.8 Million AUD | -19.86% |
| 2016 | 2.25 Million AUD | -53.05% |
| 2015 | 4.8 Million AUD | 8.14% |
| 2014 | 4.44 Million AUD | 36.53% |
| 2013 | 3.25 Million AUD | 0.0% |
| 2010 | - AUD | 0.0% |
| 2009 | - AUD | 0.0% |
| 2008 | - AUD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 30.83 Thousand AUD | -53.34% |
| 2024 FY | - AUD | -100.0% |
| 2024 Q4 | - AUD | 0.0% |
| 2024 Q2 | 30.83 Thousand AUD | 0.0% |
| 2023 Q1 | 676.28 Thousand AUD | -60.96% |
| 2023 FY | 1.48 Million AUD | -74.45% |
| 2023 Q4 | 66.09 Thousand AUD | 0.0% |
| 2023 Q3 | 66.09 Thousand AUD | -90.23% |
| 2023 Q2 | 676.28 Thousand AUD | -0.0% |
| 2022 FY | 5.81 Million AUD | 42.35% |
| 2022 Q3 | 1.73 Million AUD | 47.68% |
| 2022 Q4 | 1.73 Million AUD | 0.0% |
| 2022 Q2 | 1.17 Million AUD | 0.0% |
| 2022 Q1 | 1.17 Million AUD | -7.45% |
| 2021 Q4 | 1.26 Million AUD | 0.0% |
| 2021 Q1 | 773.5 Thousand AUD | 45.3% |
| 2021 FY | 4.08 Million AUD | 4528.99% |
| 2021 Q2 | 773.5 Thousand AUD | -0.0% |
| 2021 Q3 | 1.26 Million AUD | 63.87% |
| 2020 Q2 | 88.18 Thousand AUD | -87.64% |
| 2020 Q3 | 532.34 Thousand AUD | 503.68% |
| 2020 Q4 | 532.34 Thousand AUD | 0.0% |
| 2020 FY | 88.18 Thousand AUD | -88.94% |
| 2020 Q1 | 713.32 Thousand AUD | 521.63% |
| 2019 Q3 | 623.24 Thousand AUD | -42.95% |
| 2019 Q1 | 1.09 Million AUD | 14.79% |
| 2019 FY | 797.67 Thousand AUD | -54.08% |
| 2019 Q2 | 1.09 Million AUD | -0.0% |
| 2019 Q4 | 114.75 Thousand AUD | -81.59% |
| 2018 Q2 | 1.23 Million AUD | 0.0% |
| 2018 Q1 | 1.23 Million AUD | 34.31% |
| 2018 FY | 1.73 Million AUD | -3.84% |
| 2018 Q4 | 951.78 Thousand AUD | 0.0% |
| 2018 Q3 | 951.78 Thousand AUD | -22.88% |
| 2017 Q2 | 1.14 Million AUD | -0.0% |
| 2017 Q4 | 918.93 Thousand AUD | 0.0% |
| 2017 Q3 | 918.93 Thousand AUD | -20.07% |
| 2017 FY | 1.8 Million AUD | -19.86% |
| 2017 Q1 | 1.14 Million AUD | -1.84% |
| 2016 Q2 | 1.31 Million AUD | 0.0% |
| 2016 FY | 2.25 Million AUD | -53.05% |
| 2016 Q1 | 1.31 Million AUD | 10.6% |
| 2016 Q4 | 1.17 Million AUD | 0.0% |
| 2016 Q3 | 1.17 Million AUD | -10.87% |
| 2015 Q2 | 1.21 Million AUD | -0.0% |
| 2015 Q1 | 1.21 Million AUD | -2.51% |
| 2015 FY | 4.8 Million AUD | 8.14% |
| 2015 Q4 | 1.18 Million AUD | 0.0% |
| 2015 Q3 | 1.18 Million AUD | -2.03% |
| 2014 Q4 | 1.24 Million AUD | 0.0% |
| 2014 Q3 | 1.24 Million AUD | 27.43% |
| 2014 Q2 | 976.12 Thousand AUD | 0.0% |
| 2014 Q1 | 976.12 Thousand AUD | 2.57% |
| 2014 FY | 4.44 Million AUD | 36.53% |
| 2013 Q2 | 674.4 Thousand AUD | 0.0% |
| 2013 FY | 3.25 Million AUD | 0.0% |
| 2013 Q3 | 951.64 Thousand AUD | 41.11% |
| 2013 Q1 | 674.4 Thousand AUD | 0.0% |
| 2013 Q4 | 951.64 Thousand AUD | 0.0% |
| 2010 FY | - AUD | 0.0% |
| 2009 FY | - AUD | 0.0% |
| 2008 FY | - AUD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AdAlta Limited | 1.73 Million AUD | 100.0% |
| Acrux Limited | 5.09 Million AUD | 100.0% |
| Race Oncology Limited | 4 Million AUD | 100.0% |
| Biome Australia Limited | 13 Million AUD | 100.0% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | 100.0% |
| BTC Health Limited | 16.36 Thousand AUD | 100.0% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 100.0% |
| CSL Limited | 22.41 Billion AUD | 100.0% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 100.0% |
| Clinuvel Pharmaceuticals Limited | 88.17 Million AUD | 100.0% |
| EZZ Life Science Holdings Limited | 66.44 Million AUD | 100.0% |
| Immutep Limited | 3.5 Million AUD | 100.0% |
| Memphasys Limited | 60 Thousand AUD | 100.0% |
| Neuren Pharmaceuticals Limited | 231.92 Million AUD | 100.0% |
| Noxopharm Limited | 2.4 Million AUD | 100.0% |
| Prescient Therapeutics Limited | 3.71 Million AUD | 100.0% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | 100.0% |
| Starpharma Holdings Limited | 8.28 Million AUD | 100.0% |
| Tissue Repair Ltd | 152.24 Thousand AUD | 100.0% |
| Biotron Limited | - AUD | NaN% |
| Alterity Therapeutics Limited | 4.01 Million AUD | 100.0% |
| Anatara Lifesciences Ltd | - AUD | NaN% |
| Bio-Gene Technology Limited | 18.32 Thousand AUD | 100.0% |
| Zelira Therapeutics Limited | 94.95 Thousand AUD | 100.0% |
| Patrys Limited | 1.39 Million AUD | 100.0% |
| Orthocell Limited | 5.31 Million AUD | 100.0% |
| Imugene Limited | - AUD | NaN% |
| PYC Therapeutics Limited | 22.05 Million AUD | 100.0% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | 100.0% |
| Cynata Therapeutics Limited | 2.31 Million AUD | 100.0% |
| Arovella Therapeutics Limited | 17 Thousand AUD | 100.0% |
| Nanollose Limited | 12.5 Thousand AUD | 100.0% |
| Invex Therapeutics Ltd | 1.21 Million AUD | 100.0% |
| NeuroScientific Biopharmaceuticals Limited | - AUD | NaN% |
| Amplia Therapeutics Limited | 4.45 Million AUD | 100.0% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | 100.0% |
| Nyrada Inc. | - AUD | NaN% |
| Telix Pharmaceuticals Limited | 496.65 Million AUD | 100.0% |
| Dimerix Limited | 583.47 Thousand AUD | 100.0% |
| PharmAust Limited | - AUD | NaN% |
| AnteoTech Limited | 460.39 Thousand AUD | 100.0% |
| Paradigm Biopharmaceuticals Limited | 65.8 Thousand AUD | 100.0% |
| Recce Pharmaceuticals Ltd | - AUD | NaN% |
| Avecho Biotechnology Limited | 473.55 Thousand AUD | 100.0% |
| Actinogen Medical Limited | 9.93 Million AUD | 100.0% |
| Immuron Limited | 4.9 Million AUD | 100.0% |
| Argenica Therapeutics Limited | 2.59 Million AUD | 100.0% |